Expression of Myxovirus Resistance A (MxA) Is Associated with Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2 (HER2)–Positive Breast Cancers

다국어 초록 (Multilingual Abstract)

Purpose The prognostic significance of tumor-infiltrating lymphocytes (TILs) has been determined in breast cancers. Interferons can affect T-cell activity through direct and indirect mechanisms.
Myxovirus resistance A (MxA) is an excellent marker of interferon activity. Here, we evaluated TILs and MxA expression in human epidermal growth factor receptor 2 (HER2)–positive breast cancers.
Materials and Methods Ninety cases of hormone receptor (HR)+/HER2+ tumors and 78 cases of HR–/HER2+ tumors were included. The TILs level was assessed using hematoxylin and eosin–stained full face sections, and MxA expression was evaluated by immunohistochemistry with a tissue microarray.
Results MxA protein expression was significantly higher in tumors with high histologic grade (p=0.023) and high levels of TILs (p=0.002). High levels of TILs were correlated with high histological grade (p=0.001), negative lymphovascular invasion (p=0.007), negative lymph node metastasis (p=0.007), absence of HR expression (p < 0.001), abundant tertiary lymphoid structures (TLSs) around ductal carcinoma in situ (p=0.018), and abundant TLSs around the invasive component (p < 0.001). High levels of TILs were also associated with improved disease-free survival, particularly in HR–/HER2+ breast cancers. However, MxA was not a prognostic factor.
Conclusion High expression of MxA in tumor cells was associated with high levels of TILs in HER2-positive breast cancers. Additionally, a high level of TILs was a prognostic factor for breast cancer, whereas the level of MxA expression had no prognostic value.

참고문헌 (Reference)

• 1 Laplante M, "mTOR signaling in growth control and disease" 149 : 274-293, 2012
• 2 Simmons DP, "Type I IFN drives a distinctive dendritic cell maturation phenotype that allows continued class II MHC synthesis and antigen processing" 188 : 3116-3126, 2012
• 3 Lee HJ, "Two histopathologically different diseases : hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer" 145 : 615-623, 2014
• 4 Salgado R, "The evaluation of tumor-infiltrating lymphocytes(TILs)in breast cancer : recommendations by an International TILs Working Group 2014" 26 : 259-271, 2015
• 5 Hu JL, "Structural analysis of tumor-related single amino acid mutations in human MxA protein" 34 : 583-593, 2015
• 6 Crouse J, "Regulation of antiviral T cell responses by type I interferons" 15 : 231-242, 2015
• 7 Croner RS, "Quantitative proteome profiling of lymph node-positive vs. -negative colorectal carcinomas pinpoints MX1 as a marker for lymph node metastasis" 135 : 2878-2886, 2014
• 8 Johansson HJ, "Proteomics profiling identify CAPS as a potential predictive marker of tamoxifen resistance in estrogen receptor positive breast cancer" 12 : 8-, 2015
• 9 Lee HJ, "Prognostic significance of tumor-infiltrating lymphocytes and the tertiary lymphoid structures in HER2-positive breast cancer treated with adjuvant trastuzumab" 144 : 278-288, 2015
• 10 Takeuchi O, "Pattern recognition receptors and inflammation" 140 : 805-820, 2010
• 11 Haller O, "Mx GTPases : dynamin-like antiviral machines of innate immunity" 23 : 154-163, 2015
• 12 Schlee M, "Master sensors of pathogenic RNA : RIG-I like receptors" 218 : 1322-1335, 2013
• 13 Borden EC, "Interferons at age 50 : past, current and future impact on biomedicine" 6 : 975-990, 2007
• 14 Minn AJ, "Interferons and the immunogenic effects of cancer therapy" 36 : 725-737, 2015
• 15 Brown SG, "Interferon inducible antiviral MxA is inversely associated with prostate cancer and regulates cell cycle, invasion and docetaxel induced apoptosis" 75 : 266-279, 2015
• 16 Mushinski JF, "Inhibition of tumor cell motility by the interferoninducible GTPase MxA" 284 : 15206-15214, 2009
• 17 Martinet L, "Human solid tumors contain high endothelial venules : association with T-and B-lymphocyte infiltration and favorable prognosis in breast cancer" 71 : 5678-5687, 2011
• 18 Lee HJ, "High mobility group B1 and N1(HMGB1 and HMGN1)are associated with tumor-infiltrating lymphocytes in HER2-positive breast cancers" 467 : 701-709, 2015
• 19 Harvey JM, "Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer" 17 : 1474-1481, 1999
• 20 Calmon MF, "Epigenetic silencing of CRABP2 and MX1 in head and neck tumors" 11 : 1329-1339, 2009
• 21 Becker M, "Distinct gene expression patterns in a tamoxifensensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM" 4 : 151-168, 2005
• 22 Goc J, "Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+T cells" 74 : 705-715, 2014
• 23 안성귀, "Current Issues and Clinical Evidence in Tumor-Infiltrating Lymphocytes in Breast Cancer" 대한병리학회 49 (49): 355-363, 2015
• 24 Cancer Genome Atlas Network, "Comprehensive molecular portraits of human breast tumours" 490 : 61-70, 2012
• 25 Huber M, "Comparison of proteomic and genomic analyses of the human breast cancer cell line T47D and the antiestrogen-resistant derivative T47D-r" 3 : 43-55, 2004
• 26 Sistigu A, "Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy" 20 : 1301-1309, 2014
• 27 Stagg J, "Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy" 108 : 7142-7147, 2011
• 28 Weichselbaum RR, "An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer" 105 : 18490-18495, 2008
• 29 Farmer P, "A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer" 15 : 68-74, 2009